Prospectus
Supplement |
|
Filed Pursuant to Rule 424(b)(5) |
(To Prospectus dated June 20, 2023) |
|
Registration No. 333-272580 |
Up
to $44,246,937
![A picture containing text, font
Description automatically generated](https://www.sec.gov/Archives/edgar/data/1582554/000149315223024041/form424b5_001.jpg)
Common
Stock
On
July 2, 2020, we entered into a certain sales agreement, or the Sales Agreement, with BTIG, LLC, or BTIG, relating to our common stock
having an aggregate offering price of up to $50 million. On August 10, 2020, pursuant to the Sales Agreement, we filed a prospectus supplement
pursuant to which we could offer and sell from time to time shares of our common stock having an aggregate offering price of up to $50
million through BTIG. Of the $50 million of our common stock covered by the Sales Agreement and the related prospectus supplement, dated
August 10, 2020, as of July 5, 2023, we have issued and sold an aggregate of 3,023,147 of our common stock for gross proceeds of $5,753,063.
This
Sales Agreement prospectus and the accompanying base prospectus, which together we sometimes refer to as the prospectus, relates to the
offer and sale, from time to time, of shares of our common stock having an aggregate gross sales price of up to $44,246,937 through
BTIG in accordance with the terms of the Sales Agreement.
Sales
of our common stock, if any, under this prospectus will be made by any method that is deemed to be an “at the market offering”
as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act. BTIG is not required to sell any specific
amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales
practices, on mutually agreed terms between BTIG and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement.
BTIG
will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock on our behalf
pursuant to the Sales Agreement. In connection with the sale of the common stock on our behalf, BTIG will be deemed to be an “underwriter”
within the meaning of the Securities Act, and the compensation of BTIG will be deemed to be underwriting commissions or discounts. We
have agreed to provide indemnification and contribution to BTIG against certain civil liabilities, including liabilities under the Securities
Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Our
common stock is traded on the NYSE American LLC, or NYSE American, under the symbol “MTNB”. On July 5, 2023, the last reported
sales price of our common stock on NYSE American was $0.35 per share.
Investing
in our common stock involves risks. See “Risk Factors” beginning on page S-4 of this prospectus, and under similar headings
in the other documents that are incorporated by reference into this prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
BTIG
July
7, 2023
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS SUPPLEMENT
This
prospectus supplement relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge
you to carefully read this prospectus, together with the accompanying base prospectus and the information incorporated by reference as
described under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference”
in this prospectus, and any free writing prospectus or prospectus supplement that we have authorized for use in connection with this
offering. These documents contain important information that you should consider when making your investment decision.
This
prospectus supplement describes the terms of this offering of common stock and also adds to and updates information contained in the
documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this
prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus
that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand,
you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in
another document having a later date — for example, a document incorporated by reference into this prospectus supplement —
the statement in the document having the later date modifies or supersedes the earlier statement.
We
have not, and the sales agent has not, authorized anyone to provide you with information different than that contained or incorporated
by reference in this prospectus and any free writing prospectus or prospectus supplement that we have authorized for use in connection
with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that
others may give you. You should assume that the information appearing in this prospectus, the documents incorporated by reference herein,
and in any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering is accurate
only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed
since those dates. You should read this prospectus, the documents incorporated by reference herein, and any free writing prospectus or
prospectus supplement that we have authorized for use in connection with this offering in their entirety before making an investment
decision.
We
are offering to sell, and are seeking offers to buy, the shares only in jurisdictions where such offers and sales are permitted. The
distribution of this prospectus supplement and the offering of the shares in certain jurisdictions or to certain persons within such
jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves
about and observe any restrictions relating to the offering of the shares and the distribution of this prospectus outside the United
States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of
an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.
We
own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business.
This prospectus supplement may also contain trademarks, service marks and trade names of third parties, which are the property of their
respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this prospectus is
not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks,
service marks and trade names referred to in this prospectus may appear without the ®, TM or SM symbols,
but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our
rights or the right of the applicable licensor to these trademarks, service marks and trade names.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus supplement, including the documents that we incorporate by reference, contain forward-looking statements within the meaning
of Section 27A of the Securities Act and Section 21E of the Exchange Act. Such forward-looking statements include those that express
plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact.
These statements include, but are not limited to, statements regarding:
|
● |
our expectations
regarding clinical studies, the timing of clinical results, development timelines and regulatory filings and submissions for our
product candidates; |
|
|
|
|
● |
risks related to failure
to obtain FDA clearances or approvals and noncompliance with FDA regulations; |
|
|
|
|
● |
the time, resources, and
expense required to develop and conduct clinical trials and seek regulatory approvals for our product candidates |
|
|
|
|
● |
the success of competing
therapies and products that are or may become available; |
|
|
|
|
● |
uncertainties of government
and third party payor reimbursement; |
|
|
|
|
● |
the performance of third
parties, including contract research organizations and third-party manufacturers; |
|
|
|
|
● |
the cost of preparing,
filing, prosecuting, defending, and enforcing patent claims and other patent related costs, including litigation costs and the results
of such litigation; |
|
|
|
|
● |
our liquidity and our expectations
regarding our needs for and ability to raise additional capital; |
|
|
|
|
● |
the amount, and our expected
uses, of the net proceeds of this offering; and |
|
|
|
|
● |
the impact the COVID-19
pandemic will have on our ability to advance our clinical development programs. |
These
forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and
uncertainties known and unknown to us that could cause actual results and developments to differ materially from those expressed or implied
in such statements, including the risks described under “Risk Factors” in this prospectus and our Annual Report on Form 10-K
for the year ended December 31, 2022 as updated by our subsequent filings under the Exchange Act, each of which is incorporated by reference
in this prospectus in their entirety.
In
some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,”
“estimates,” “plans,” “believes,” “seeks,” “may,” “should”, “could”
or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties
that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their
entirety by reference to the factors discussed throughout this prospectus.
You
should read this prospectus and the documents that we reference herein and therein, completely and with the understanding that our actual
future results may be materially different from what we expect. You should assume that the information appearing in this prospectus and
the documents incorporated by reference is accurate as of their respective dates. Our business, financial condition, results of operations
and prospects may change. We may not update these forward-looking statements, even though our situation may change in the future, unless
required by law to update and disclose material developments related to previously disclosed information. We qualify all of the information
presented in this prospectus, and particularly our forward-looking statements, by these cautionary statements.
PROSPECTUS
SUMMARY
The
following summary is qualified in its entirety by, and should be read together with, the more detailed information and financial statements
and related notes thereto appearing elsewhere or incorporated by reference in this prospectus. Before you decide to invest in our securities,
you should read the entire prospectus carefully, including the risk factors and the financial statements and related notes included or
incorporated by reference in this prospectus.
Unless
otherwise indicated or unless the context requires otherwise, this prospectus includes the accounts of Matinas Biopharma Holdings, Inc.,
a Delaware corporation and its wholly-owned subsidiaries, collectively referred to as “we”, “us”, “Matinas”
or the “Company”.
Overview
We
are a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using our lipid nanocrystal (LNC) platform
delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company is developing an internal portfolio
of products and strives to be the partner of choice for leading pharmaceutical companies seeking to develop novel formulations that capitalize
on the unique characteristics of the LNC Platform to facilitate, enhance and optimize the delivery of complex nucleic acids. Our current
internal pipeline consists of MAT2203 (oral amphotericin B), a highly potent antifungal drug which we have successfully made oral, safe,
and well-tolerated for patients. We also have internal discovery programs ongoing in the formulation and delivery of small oligonucleotides,
namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs). We are also intent on expanding the application
of our LNC Platform through collaborations with well-respected pharmaceutical companies whose molecules and compounds benefit from the
unique capabilities of our delivery technology, which can provide oral bioavailability and facilitate non-toxic and efficient intracellular
delivery of nucleic acids, particularly in the fields of mRNA and DNA.
Corporate
Information
We
were incorporated in Delaware under the name Matinas BioPharma Holdings, Inc. in May 2013. We have two operating subsidiaries: Matinas
BioPharma, Inc., a Delaware corporation originally formed on August 12, 2011 as Nereus BioPharma LLC, and Matinas BioPharma Nanotechnologies,
Inc., a Delaware corporation originally formed on January 29, 2015 as Aquarius Biotechnologies, Inc.
Our
principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921, and our telephone number is
(908) 443-1860. Our website address is www.matinasbiopharma.com. Our website and the information contained on, or that can be accessed
through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should
not rely on our website or any such information in making your decision whether to purchase our securities.
The Offering
Common stock offered by us: |
|
Shares
of our common stock having an aggregate offering price of up to $44,246,937. |
|
|
|
Manner of offering: |
|
“At the market offering”
that may be made from time to time through our sales agent, BTIG. See “Plan of Distribution” on page S-9. |
|
|
|
Use of proceeds: |
|
We intend to use the net
proceeds, if any, from this offering, for working capital and general corporate purposes. See “Use of Proceeds” on page
S-5. |
|
|
|
Risk Factors: |
|
Investing in our common
stock involves significant risks. See “Risk Factors” beginning on page S-4 of this prospectus supplement and other information
included or incorporated by reference into this prospectus supplement for a discussion of factors you should carefully consider before
investing in our securities. |
|
|
|
NYSE American symbol: |
|
“MTNB” |
RISK
FACTORS
Investing
in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should carefully
consider the specific risk factors discussed in the sections entitled “Risk Factors” contained in our annual report on Form
10-K for the fiscal year ended December 31, 2022 under the heading “Item 1A. Risk Factors,” and as described or may be described
in any subsequent quarterly report on Form 10-Q under the heading “Item 1A. Risk Factors,” as well as in any applicable prospectus
supplement and contained or to be contained in our filings with the SEC and incorporated by reference in this prospectus, together with
all of the other information contained in this prospectus, or any applicable prospectus supplement. For a description of these reports
and documents, and information about where you can find them, see “Where You Can Find More Information” and “Incorporation
of Certain Information by Reference.” If any of the risks or uncertainties described in our SEC filings or any prospectus supplement
or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially
and adversely affected.
Risks
Relating to this Offering
We
may allocate the net proceeds from this offering in ways that you or other stockholders may not approve.
We
currently intend to use the net proceeds of this offering, if any, for working capital and general corporate purposes, which may include
capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions
of new technologies and investments, and the financing of possible acquisitions or business expansions. This expected use of the net
proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of
our actual expenditures may vary significantly depending on numerous factors, including the progress of our development efforts, the
status of and results from clinical trials, as well as any third party intellectual property or other assets that we may opportunistically
identify and seek to license or acquire or any collaborations that we may enter into with third parties for our product candidates, and
any unforeseen cash needs. Because the number and variability of factors that will determine our use of the proceeds from this offering,
their ultimate use may vary substantially from their currently intended use. As a result, our management will retain broad discretion
over the allocation of the net proceeds from this offering and could spend the proceeds in ways that do not necessarily improve our operating
results or enhance the value of our common stock. See “Use of Proceeds.”
You
may experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase in the offering.
In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to
you.
The
offering price per share in this offering may exceed the pro forma net tangible book value per share of our common stock outstanding
as of March 31, 2023. Assuming that we sell an aggregate of approximately 126.4 million shares of our common stock at a price of $0.35
per share, the last reported sale price of our common stock on the NYSE American on July 5, 2023, for aggregate gross proceeds of approximately
$44.2 million, and after deducting commissions and estimated aggregate offering expenses payable by us, you will experience immediate
dilution of $0.14 per share, representing the difference between our pro forma as adjusted net tangible book value per share as of March
31, 2023 after giving effect to this offering and the assumed offering price. See the section titled “Dilution” below for
a more detailed illustration of the dilution you would incur if you participate in this offering. In addition, to the extent we need
to raise additional capital in the future and we issue additional shares of common stock or securities convertible or exchangeable for
our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our
common stock offered in this offering.
Our
certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types
of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable
judicial forum for disputes with us or our directors, officers, employees or agents.
In
addition, our certificate of incorporation requires that, to the fullest extent permitted by law, and unless the Company consents in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted
by law, be the sole and exclusive forum for each of the following:
|
● |
any derivative action or
proceeding brought in the name or right of the Company or on its behalf, |
|
|
|
|
● |
any action asserting a
claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Company to the Company or the Company’s
stockholders, |
|
|
|
|
● |
any action asserting a
claim against the Company or any director or officer of the Company arising pursuant to, or a claim against the Company or any director
or officer of the Company with respect to the interpretation or application of any provision of, the Delaware General Corporation
Law, the certificate of incorporation or the bylaws of the Company, or |
|
|
|
|
● |
any action asserting a
claim governed by the internal affairs doctrine. |
Because
the applicability of the exclusive forum provision is limited to the extent permitted by law, we believe that the exclusive forum provision
would not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction, and that federal courts have concurrent jurisdiction over all suits brought to enforce any duty or
liability created by the Securities Act. We note that there is uncertainty as to whether a court would enforce the provision and that
investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe this
provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies,
the provision may have the effect of discouraging lawsuits against our directors and officers.
USE
OF PROCEEDS
We
currently intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes.
The
timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated
growth of our business. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds
to us from this offering. As a result, our management will have broad discretion regarding the timing and application of the net proceeds
from this offering. Pending their ultimate use, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing
instruments.
MARKET
PRICE OF OUR COMMON STOCK
Our
common stock is presently listed on NYSE American under the symbol “MTNB”. On July 5, 2023, the last reported sale price
of our common stock was $0.35.
Holders
As
of July 5, 2023 we had 104 registered holders of record of our common stock. A substantially greater number of holders of our common
stock are “street name” or beneficial holders, whose shares of record are held through banks, brokers, other financial institutions
and registered clearing agencies.
DIVIDEND
POLICY
We
have never declared or paid cash dividends on our capital stock. We currently intend to retain our future earnings, if any, for use in
our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will
be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating
results, current and anticipated cash needs and plans for expansion.
DILUTION
If
you purchase shares of our common stock in this offering, your interest will be diluted to the extent of the difference between the public
offering price per share and the net tangible book value per share of our common stock after this offering. We calculate net tangible
book value per share by dividing our net tangible assets (tangible assets less total liabilities) by the number of shares of our common
stock issued and outstanding as of March 31, 2023.
Our
historical net tangible book value at March 31, 2023 was approximately $28.3 million or $0.13 per share of our common stock. After
giving effect to the sale of our common stock in the aggregate amount of approximately $44.2 million in this offering, at an assumed
offering price of $0.35 per share, the last reported sale price of our common stock on NYSE on July
5, 2023, and after deducting estimated offering expenses and commissions payable by us, our
adjusted net tangible book value as of March 31, 2023 would have been approximately $71.2 million, or $0.21 per share of our common
stock. This represents an immediate increase in the net tangible book value of $0.08 per share of our common stock to our existing
stockholders and an immediate dilution in net tangible book value of $0.14 per share of our common stock to new investors. The
following table illustrates per share dilution:
Assumed public offering price per share | |
$ | 0.35 | |
Net tangible book value per share as of March 31, 2023 | |
$ | 0.13 | |
Increase in net tangible book value per share attributable to this offering | |
$ | 0.08 | |
Adjusted net tangible book value per share as of March 31, 2023, after giving effect to this
offering | |
$ | 0.21 | |
Dilution per share to new investors purchasing shares in this offering | |
$ | 0.14 | |
The
table above assumes for illustrative purposes that an aggregate of approximately 126.4 milion shares of our common stock are sold at
a price of $0.35 per share, the last reported sale price of our common stock on the NYSE American on July 5, 2023, for aggregate gross
proceeds of approximately $44.2 million. The shares sold in this offering, if any, will be sold from time to time at various prices.
An increase of $0.10 per share in the price at which the shares are sold from the assumed offering price of $0.35 per share shown in
the table above, assuming all of our common stock in the aggregate amount of $44.2 million is sold at that price, would increase our
adjusted net tangible book value per share after the offering to $0.23 per share and would increase the dilution in net tangible book
value per share to new investors in this offering to $0.22 per share, after deducting estimated offering expenses and commissions payable
by us. A decrease of $0.10 per share in the price at which the shares are sold from the assumed offering price of $0.35 per share shown
in the table above, assuming all of our common stock in the aggregate amount of $44.2 million is sold at that price, would increase our
adjusted net tangible book value per share after the offering to $0.18 per share and would decrease the dilution in net tangible book
value per share to new investors in this offering to $0.07 per share, after deducting estimated offering expenses and commissions payable
by us. This information is supplied for illustrative purposes only.
The
information above is based on 217,264,526 shares of our common stock outstanding as of March
31, 2023, and excludes:
|
● |
34,677,699
shares of our common stock issuable upon the exercise
of stock options outstanding at a weighted average exercise price of $1.08 per share; |
|
|
|
|
● |
238,000
shares of our common stock issuable upon the exercise
of warrants outstanding at a weighted average exercise price of $0.75 per share, and which expired on June 21, 2023; |
|
|
|
|
● |
3,000,000 shares issuable
upon achievement of certain milestones pursuant to the terms of our merger agreement with Aquarius Biotechnologies, Inc.; and |
|
|
|
|
● |
14,935,405
additional shares of our common stock available
for future issuance under our equity compensation plan. |
To
the extent that outstanding options or warrants are exercised, or we issue other shares, investors purchasing shares in this offering
could experience further dilution. In addition, to the extent that we raise additional capital through the sale of equity or convertible
debt securities, the issuance of those securities could result in further dilution to our stockholders.
PLAN
OF DISTRIBUTION
We
have entered into the sales agreement with BTIG under which we may issue and sell shares of our common stock having an aggregate offering
price of up to $50 million from time to time through BTIG, acting as our sales agent, which includes $5,753,063 of our common stock that have already been sold pursuant to the Sales Agreement through July 5, 2023. The sales of our common
stock, if any, under this prospectus supplement will be made at market prices by any method deemed to be an “at the market offering”
as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the NYSE, on any other existing trading market
for our common stock, or to or through a market maker.
Each
time that we wish to issue and sell shares of our common stock under the sales agreement, we will provide BTIG with a placement notice
describing the amount of shares to be sold, the time period during which sales are requested to be made, any limitation on the amount
of shares of common stock that may be sold in any single day, any minimum price below which sales may not be made or any minimum price
requested for sales in a given time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice,
BTIG, acting as our sales agent, will use commercially reasonable efforts, consistent with its normal trading and sales practices and
applicable state and federal laws, rules and regulations and the rules of the NYSE American, to sell shares of our common stock under
the terms and subject to the conditions of the placement notice and the sales agreement. We or BTIG may suspend the offering of common
stock pursuant to a placement notice upon notice and subject to other conditions. BTIG, in its sole discretion, may decline to accept
any placement notice.
BTIG
will provide written confirmation to us no later than the opening of the trading day on the NYSE American following the trading day on
which shares of our common stock are sold through BTIG as sales agent under the sales agreement. Each confirmation will include the number
of shares sold on the preceding day, the net proceeds to us and the commissions payable by us to BTIG in connection with the sales.
Settlement
for sales of common stock under the sales agreement will occur on the second trading day following the date on which such sales are made
(or on such other date as is industry practice for regular-way trading), unless otherwise specified in the applicable placement notice,
in return for payment of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow,
trust or similar account. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities
of The Depository Trust Company or by such other means as we and BTIG may agree upon.
We
will pay BTIG commissions for its services in acting as our sales agent in the sale of our common stock pursuant to the sales agreement.
BTIG will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock on our
behalf pursuant to the sales agreement. We also reimbursed BTIG for its reasonable out-of-pocket expenses, including the fees and disbursements
of BTIG’s counsel, incurred in connection with entering into the sales agreement, in the amount of $65,000, and fees and disbursements
of BTIG’s counsel on a quarterly basis not to exceed $7,500.
We
estimate that the total expenses for this offering, excluding compensation payable to BTIG and certain expenses reimbursable to BTIG
under the terms of the sales agreement, will be approximately $175,000. The remaining sales proceeds, after deducting any expenses payable
by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales,
will equal our net proceeds for the sale of such common stock.
Because
there are no minimum sale requirements as a condition to this offering, the actual total public offering price, commissions and net proceeds
to us, if any, are not determinable at this time. The actual dollar amount and number of shares of common stock we sell through this
prospectus supplement will be dependent, among other things, on market conditions and our capital raising requirements.
We
will report at least quarterly the number of shares of common stock sold through BTIG under the sales agreement, the net proceeds to
us and the compensation paid by us to BTIG in connection with the sales of common stock.
In
connection with the sale of the common stock on our behalf, BTIG will be deemed to be an “underwriter” within the meaning
of the Securities Act, and the compensation of BTIG will be deemed to be underwriting commissions or discounts. We have agreed to provide
indemnification and contribution to BTIG against certain civil liabilities, including liabilities under the Securities Act or the Exchange
Act.
BTIG
will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement
if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act. As our sales agent,
BTIG will not engage in any transactions that stabilizes our common stock.
The
offering pursuant to the sales agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the
sales agreement and (ii) termination of the sales agreement as permitted therein. We may terminate the sales agreement in our sole discretion
at any time by giving 10 days’ prior notice to BTIG. BTIG may terminate the sales agreement under the circumstances specified in
the sales agreement and in its sole discretion at any time by giving 10 days’ prior notice to us.
The
sales agreement has been filed as an exhibit to a current report on Form 8-K that we filed with the SEC in connection with this offering
and is incorporated into this prospectus supplement by reference.
BTIG
and/or its affiliates may in the future provide, various investment banking and other financial services for us, for which services may
in the future receive customary fees.
LEGAL
MATTERS
The
validity of the shares of common stock offered by this prospectus were passed upon by Lowenstein Sandler LLP, New York, New York. Certain
matters will be passed upon for BTIG by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York.
EXPERTS
The
consolidated balance sheets of Matinas BioPharma Holdings, Inc. and Subsidiaries (the “Company”) as of December 31, 2022
and 2021, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for
each of the years then ended, have been audited by EisnerAmper LLP, an independent registered public accounting firm, as stated in their
report which is incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance on
the report of such firm given upon their authority as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus supplement is part of the registration statement on Form S-3 we filed with the Securities and Exchange Commission, or SEC,
under the Securities Act, and does not contain all the information set forth in the registration statement. Whenever a reference is made
in this prospectus supplement to any of our contracts, agreements or other documents, the reference may not be complete, and you should
refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by
reference into this prospectus for a copy of such contract, agreement or other document. You may inspect a copy of the registration statement,
including the exhibits and schedules, without charge, at the SEC’s public reference room mentioned below, or obtain a copy from
the SEC upon payment of the fees prescribed by the SEC.
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read, without charge, and copy
the documents we file at the SEC’s public reference rooms in Washington, D.C. at 100 F Street, NE, Room 1580, Washington, DC 20549.
You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330
for further information on the public reference rooms. Our SEC filings are also available to the public at no cost from the SEC’s
website at http://www.sec.gov.
INCORPORATION
OF DOCUMENTS BY REFERENCE
We
incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this prospectus, and any
future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (unless otherwise noted, the SEC
file number for each of the documents listed below is 001-36019):
|
● |
Annual Report
on Form 10-K for the year ended December 31, 2022, filed on March 15, 2023; |
|
|
|
|
● |
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 10, 2023; |
|
|
|
|
● |
Definitive Proxy Statement
on Schedule 14A, filed on September 9, 2022; |
|
|
|
|
● |
Current Reports on Form
8-K, filed on January 12, 2023, January 30, 2023, March 15, 2023, April 18, 2023 and May 10, 2023 (other than any portions thereof
deemed furnished and not filed); and |
|
|
|
|
● |
The description of our
common stock contained in our Form 8-A, filed on March 1, 2017. |
We
also incorporate by reference into this prospectus additional documents (other than current reports furnished under Item 2.02 or Item
7.01 of Form 8-K and exhibits on such form that are related to such items) that we may file with the SEC under Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with
the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding
any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by
reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that
statement.
This
prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated
by reference in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We
have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus, or the date of the documents incorporated by reference in this prospectus.
We
will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no
cost to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus.
You
may request, and we will provide you with, a copy of these filings, at no cost, by contacting us at:
Investor
Relations Department
Matinas
BioPharma Holdings, Inc.
1545
Route 206 South
Suite
302
Bedminster,
NJ 07921
Telephone
number: 908-443-1860
PROSPECTUS
$200,000,000
![https:||www.sec.gov|Archives|edgar|data|1582554|000149315220000492|image_003.jpg](https://www.sec.gov/Archives/edgar/data/1582554/000149315223024041/forms424b5_01.jpg)
Common
Stock
Preferred
Stock
Warrants
Debt
Securities
Subscription
Rights
Units
We
may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, warrants, debt securities,
subscription rights or units having an aggregate initial offering price not exceeding $200,000,000. The preferred stock, warrants, debt
securities, subscription rights and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other
securities of ours and have not been approved for listing on any market or exchange, and we have not made any application for such listing.
Each
time we sell a particular class or series of securities, we will provide specific terms of the securities offered in a supplement to
this prospectus. The prospectus supplement may also add, update or change information in this prospectus. You should read this prospectus
and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference into this
prospectus, carefully before you invest in any securities.
This
prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities.
Our
common stock is traded on the NYSE American LLC, or NYSE American, under the symbol “MTNB”. On June 8, 2023, the last
reported sales price of our common stock on NYSE American was $0.37 per share. Each prospectus supplement will indicate if the
securities offered thereby will be listed on any securities exchange.
These
securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or dealers
or through a combination of these methods on a continuous or delayed basis. See “Plan of Distribution” in this prospectus.
We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents,
underwriters or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose
their names and the nature of our arrangements with them in a prospectus supplement. The net proceeds we expect to receive from any such
sale will also be included in a prospectus supplement.
Investing
in our securities involves various risks. See “Risk Factors” beginning on page 2 of this prospectus and in the applicable
prospectus supplement, and in the risks discussed in the documents incorporated by reference in this prospectus and in the applicable
prospectus supplement, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange
Commission. You should carefully read and consider these risk factors before you invest in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
This
prospectus is dated June 20, 2023
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a shelf registration statement that we filed with the Securities and Exchange Commission (the “SEC”)
using a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities
described in this prospectus in one or more offerings from time to time having an aggregate initial offering price of $200,000,000. This
prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide you
with a prospectus supplement that describes the specific amounts, prices and terms of the securities we offer. The prospectus supplement
also may add, update or change information contained in this prospectus. You should read carefully both this prospectus and any prospectus
supplement together with additional information described below under the caption “Where You Can Find More Information.”
This
prospectus does not contain all the information provided in the registration statement we filed with the SEC. You should read both this
prospectus, including the section titled “Risk Factors,” and the accompanying prospectus supplement, together with the additional
information described under the heading “Where You Can Find More Information.”
You
should rely only on the information contained or incorporated by reference in this prospectus or a prospectus supplement. We have not
authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information,
you should not rely on it. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities in
any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any
prospectus supplement, as well as information we have previously filed with the SEC and incorporated by reference, is accurate as of
the date on the front of those documents only. Our business, financial condition, results of operations and prospects may have changed
since those dates.
OUR
BUSINESS
The
following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus.
Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully
read this prospectus, including the documents incorporated by reference, which are described under “Incorporation of Certain Information
by Reference” and “Where You Can Find More Information” in this prospectus. You should also carefully consider the
matters discussed in the section titled “Risk Factors” in this prospectus and in other periodic reports incorporated by reference
herein.
Overview
We
are a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using our lipid nanocrystal (LNC) platform
delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company is developing an internal portfolio
of products and strives to be the partner of choice for leading pharmaceutical companies seeking to develop novel formulations that capitalize
on the unique characteristics of the LNC Platform to facilitate, enhance and optimize the delivery of complex nucleic acids. Our current
internal pipeline consists of MAT2203 (oral amphotericin B), a highly potent antifungal drug which we have successfully made oral, safe,
and well-tolerated for patients. We also have internal discovery programs ongoing in the formulation and delivery of small oligonucleotides,
namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs). We are also intent on expanding the application
of our LNC Platform through collaborations with well-respected pharmaceutical companies whose molecules and compounds benefit from the
unique capabilities of our delivery technology, which can provide oral bioavailability and facilitate non-toxic and efficient intracellular
delivery of nucleic acids, particularly in the fields of mRNA and DNA.
Corporate
Information
We
were incorporated in Delaware under the name Matinas BioPharma Holdings, Inc. in May 2013. We have two operating subsidiaries: Matinas
BioPharma, Inc., a Delaware corporation originally formed on August 12, 2011 as Nereus BioPharma LLC, and Matinas BioPharma Nanotechnologies,
Inc., a Delaware corporation originally formed on January 29, 2015 as Aquarius Biotechnologies, Inc.
Our
principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921, and our telephone number is
(908) 484-880-5443. Our website address is www.matinasbiopharma.com. Our website and the information contained on, or that can
be accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus.
You should not rely on our website or any such information in making your decision whether to purchase our securities. Risks Associated
with Our Business and this Offering
Our
business and our ability to implement our business strategy are subject to numerous risks, as more fully described in the section of
this prospectus entitled “Risk Factors.” You should read these risks before you invest in our securities. We may be unable,
for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks associated with
our business include:
|
● |
We
have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future,
and our future profitability is uncertain. |
|
|
|
|
● |
Our
product candidates must undergo rigorous clinical testing. Such clinical testing may fail to demonstrate safety and efficacy and
any of our product candidates could cause undesirable side effects, which would substantially delay or prevent regulatory approval
or commercialization. |
|
|
|
|
● |
We
are dependent on patents and proprietary technology. If we fail to adequately protect this intellectual property or if we otherwise
do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer. |
|
|
|
|
● |
If
our competitors are able to develop and market products that are more effective, safer or more affordable than ours are, or obtain
marketing approval before we do, our commercial opportunities may be limited. |
|
|
|
|
● |
We
may not be able to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical
studies and clinical trials. |
|
|
|
|
● |
If
you purchase our securities in this offering, you may incur dilution. |
|
|
|
|
● |
We
will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. |
|
|
|
|
● |
Our
ability to advance our clinical development programs could be impacted by the COVID-19 pandemic. |
RISK
FACTORS
Investing
in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, you should carefully
consider the specific risk factors discussed in the sections entitled “Risk Factors” contained in our annual report on Form
10-K for the fiscal year ended December 31, 2022 under the heading “Item 1A. Risk Factors,” and as described or may be described
in any subsequent quarterly report on Form 10-Q under the heading “Item 1A. Risk Factors,” as well as in any applicable prospectus
supplement and contained or to be contained in our filings with the SEC and incorporated by reference in this prospectus, together with
all of the other information contained in this prospectus, or any applicable prospectus supplement. For a description of these reports
and documents, and information about where you can find them, see “Where You Can Find More Information” and “Incorporation
of Certain Information by Reference.” If any of the risks or uncertainties described in our SEC filings or any prospectus supplement
or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially
and adversely affected.
In
that case, the trading price of our securities could decline and you might lose all or part of the value of your investment.
DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent,
contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements
are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown
that could cause actual results and developments to differ materially from those expressed or implied in such statements.
In
some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,”
“estimates,” “plans,” “believes,” “seeks,” “may,” “should”, “could”
or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties
that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their
entirety by reference to the factors discussed throughout this prospectus.
You
should read this prospectus and any accompanying prospectus supplement and the documents that we reference herein and therein and have
filed as exhibits to the registration statement, of which this prospectus is part, completely and with the understanding that our actual
future results may be materially different from what we expect. You should assume that the information appearing in this prospectus and
any accompanying prospectus supplement is accurate as of the date on the front cover of this prospectus or such prospectus supplement
only. Because the risk factors referred to above, as well as the risk factors referred to on page 2 of this prospectus and incorporated
herein by reference, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements
made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events
or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge
from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each
factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statements. We qualify all of the information presented in this prospectus and any accompanying
prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.
USE
OF PROCEEDS
Except
as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered
by this prospectus for working capital and general corporate purposes.
The
intended application of proceeds from the sale of any particular offering of securities using this prospectus will be described in the
accompanying prospectus supplement relating to such offering. The precise amount and timing of the application of these proceeds will
depend on our funding requirements and the availability and costs of other funds.
THE
SECURITIES WE MAY OFFER
The
descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize all the material
terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating
to any securities the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable prospectus
supplement, the terms of the securities may differ from the terms we have summarized below. We will also include in the prospectus supplement
information, where applicable, about material United States federal income tax considerations relating to the securities, and the securities
exchange, if any, on which the securities will be listed.
We
may sell from time to time, in one or more offerings:
|
● |
common
stock; |
|
● |
preferred
stock; |
|
● |
debt
securities; |
|
● |
warrants
to purchase shares of common stock, preferred stock or other securities; |
|
● |
subscription
rights, and |
|
● |
units
consisting of any combination of the securities listed above. |
In
this prospectus, we refer to the common stock, preferred stock, debt securities, warrants, subscription rights and units collectively
as “securities.” The total dollar amount of all securities that we may sell will not exceed $200,000,000.
If
we issue debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar
amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original
principal amount of the debt securities.
When
particular securities are offered, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering
and sale of the offered securities.
DESCRIPTION
OF COMMON STOCK
The
following is a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws.
The summary does not purport to be complete and is qualified in its entirety by reference to our articles of incorporation and bylaws,
each as amended, and to the provisions of Chapters 78 and 92A of the Delaware General Corporation Law, as amended.
General
Our
authorized capital stock consists of:
|
● |
500,000,000
shares of common stock, par value $0.0001 per share; and |
|
● |
10,000,000
shares of preferred stock, par value $0.0001 per share, of which as of the date of this prospectus 8,000 shares have been designated
as Series B Preferred Stock. |
As
of close of business on June 8, 2023, 217,264,526 shares of common stock were issued and outstanding.
The
additional shares of our authorized stock available for issuance might be issued at times and under circumstances so as to have a dilutive
effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board of directors to
issue additional shares of stock could enhance the board’s ability to negotiate on behalf of the stockholders in a takeover situation
but could also be used by the board to make a change-in-control more difficult, thereby denying stockholders the potential to sell their
shares at a premium and entrenching current management. The following description is a summary of the material provisions of our capital
stock. You should refer to our amended and restated certificate of incorporation and by-laws, both of which are on file with the SEC
as exhibits to previous SEC filings, for additional information. The summary below is qualified by provisions of applicable law.
Common
Stock
Voting.
The holders of our common stock are entitled to one vote for each share held of record on all matters on which the holders are entitled
to vote (or consent to).
Dividends.
The holders of our common stock are entitled to receive, ratably, dividends only if, when and as declared by our Board of Directors
out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common
stock (including the common stock).
Liquidation
Rights. In the event of our liquidation, dissolution or winding-up, the holders of our common stock are entitled to share, ratably,
in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital
stock having preference over the common stock (including the common stock).
Conversion
Rights. The holders of our common stock have no conversion rights.
Preemptive
and Similar Rights. The holders of our common stock have no preemptive or similar rights.
Redemption/Put
Rights. There are no redemption or sinking fund provisions applicable to the common stock. All of the outstanding shares of our common
stock are fully-paid and nonassessable.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is VStock Transfer, LLC.
DESCRIPTION
OF PREFERRED STOCK
We
are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, rights, and
preferences as may be determined from time to time by our Board of Directors. Accordingly, our Board of Directors is empowered, without
stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect
the voting power or other rights of the holders of our common stock. The issuance of preferred stock could have the effect of restricting
dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or
delaying or preventing a change in control of our company, all without further action by our stockholders.
Our
board of directors has the authority, within the limitations and restrictions prescribed by law and without stockholder approval, to
provide by resolution for the issuance of shares of preferred stock, and to fix the rights, preferences, privileges and restrictions
thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference and the number of shares
constituting any series of the designation of such series, by delivering an appropriate certificate of amendment to our amended and restated
certificate of incorporation to the Delaware Secretary of State pursuant to the Delaware General Corporation Law (the “DGCL”).
The issuance of preferred stock could have the effect of decreasing the market price of the common stock, impeding or delaying a possible
takeover and adversely affecting the voting and other rights of the holders of our common stock.
If
we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus
supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the
extent required, this description will include:
|
● |
the
title and stated value; |
|
● |
the
number of shares offered, the liquidation preference per share and the purchase price; |
|
● |
the
dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; |
|
● |
whether
dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; |
|
● |
the
procedures for any auction and remarketing, if any; |
|
● |
the
provisions for a sinking fund, if any; |
|
● |
the
provisions for redemption, if applicable; |
|
● |
any
listing of the preferred stock on any securities exchange or market; |
|
● |
whether
the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated)
and conversion period; |
|
● |
whether
the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated)
and exchange period; |
|
● |
voting
rights, if any, of the preferred stock; |
|
● |
a
discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; |
|
● |
the
relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding
up of the affairs of Matinas; and |
|
● |
any
material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred
stock as to dividend rights and rights upon liquidation, dissolution or winding up of Matinas. |
Transfer
Agent and Registrar for Preferred Stock
The
transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement.
Anti-takeover
Effects of Delaware Law and of our Amended and Restated Certificate of Incorporation
The
following paragraphs summarize certain provisions of the DGCL and our amended and restated certificate of incorporation that may have
the effect of discouraging an acquisition of Matinas. The summary does not purport to be complete and is subject to and qualified in
its entirety by reference to the DGCL and our amended and restated certificate of incorporation and by-laws, copies of which are on file
with the SEC. Please refer to “Additional Information” below for directions on obtaining these documents.
Section
203 of the Delaware General Corporation Law
We
are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:
|
● |
before
such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
the stockholder becoming an interested stockholder; |
|
● |
upon
completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
|
● |
on
or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting
of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that
is not owned by the interested stockholder. |
In
general, Section 203 defines business combination to include the following:
|
● |
any
merger or consolidation involving the corporation and the interested stockholder; |
|
● |
any
sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
|
● |
subject
to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder; |
|
● |
any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
of the corporation beneficially owned by the interested stockholder; or |
|
● |
the
receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or
through the corporation. |
In
general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates
and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own,
15% or more of the outstanding voting stock of the corporation.
Certificate
of Incorporation and Bylaws
Our
certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals
or tender offers or delaying or preventing a change of control of our company. These provisions are as follows:
|
● |
they
provide that special meetings of stockholders may be called only by the board of directors, President or our Chairman of the Board
of Directors, or at the request in writing by stockholders of record owning at least fifty (50%) percent of the issued and outstanding
voting shares of common stock; |
|
● |
they
do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority stockholder holding
a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have
the effect of limiting the ability of minority stockholders to effect changes in our board of directors; and |
|
● |
they
allow us to issue “blank check” preferred stock, the terms of which may be established and shares of which may be issued
without stockholder approval. |
In
addition, our certificate of incorporation requires that, to the fullest extent permitted by law, and unless the Company consents in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted
by law, be the sole and exclusive forum for each of the following:
|
● |
any
derivative action or proceeding brought in the name or right of the Company or on its behalf, |
|
|
|
|
● |
any
action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Company to the Company
or the Company’s stockholders, |
|
|
|
|
● |
any
action asserting a claim against the Company or any director or officer of the Company arising pursuant to, or a claim against the Company
or any director or officer of the Company with respect to the interpretation or application of any provision of, the Delaware General
Corporation Law, the certificate of incorporation or the bylaws of the Company, or |
|
● |
any
action asserting a claim governed by the internal affairs doctrine. |
Because
the applicability of the exclusive forum provision is limited to the extent permitted by law, we believe that the exclusive forum provision
would not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction, and that federal courts have concurrent jurisdiction over all suits brought to enforce any duty or
liability created by the Securities Act. We note that there is uncertainty as to whether a court would enforce the provision and that
investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe this
provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies,
the provision may have the effect of discouraging lawsuits against our directors and officers.
Potential
Effects of Authorized but Unissued Stock
We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional
shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions
or payment as a dividend on the capital stock.
The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly
to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to
obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.
In addition, the board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including
voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock,
all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our amended and restated certificate
of incorporation. The purpose of authorizing the board of directors to issue preferred stock and to determine the rights and preferences
applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred
stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could
have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority
of our outstanding voting stock.
DESCRIPTION
OF STOCK WARRANTS
We
summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides otherwise.
This summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable
warrant certificate and warrant agreement. These documents have been or will be included or incorporated by reference as exhibits to
the registration statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement. You
should also read the prospectus supplement, which will contain additional information and which may update or change some of the information
below.
General
We
may issue, together with common or preferred stock as units or separately, warrants for the purchase of shares of our common stock, shares
of our preferred stock, debt securities or other securities. The terms of each warrant will be discussed in the applicable prospectus
supplement relating to the particular series of warrants. The form(s) of certificate representing the warrants and/or the warrant agreement,
will be, in each case, filed with the SEC as an exhibit to a document incorporated by reference in the registration statement of which
this prospectus is a part on or prior to the date of any prospectus supplement relating to an offering of the particular warrant. The
following summary of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by
reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants.
The
prospectus supplement relating to any series of warrants that are offered by this prospectus will describe, among other things, the following
terms to the extent they are applicable to that series of warrants:
|
● |
the
procedures and conditions relating to the exercise of the warrants; |
|
● |
the
number of shares of our common or preferred stock, if any, issued with the warrants; |
|
● |
the
date, if any, on and after which the warrants and any related shares of our common or preferred stock will be separately transferable; |
|
● |
the
offering price of the warrants, if any; |
|
● |
the
number of shares of our common or preferred stock, debt securities or other securities which may be purchased upon exercise of the
warrants and the price or prices at which such securities may be purchased upon exercise; |
|
● |
the
date on which the right to exercise the warrants will begin and the date on which the right will expire; |
|
● |
a
discussion of any material United States federal income tax considerations applicable to the exercise of the warrants; |
|
● |
anti-dilution
provisions of the warrants, if any; |
|
● |
call
provisions of the warrants, if any; and |
|
● |
any
other material terms of the warrants. |
Each
warrant may entitle the holder to purchase for cash, or, in limited circumstances, by effecting a cashless exercise for, the number of
shares of our common or preferred stock at the exercise price that is described in the applicable prospectus supplement. Warrants will
be exercisable during the period of time described in the applicable prospectus supplement. After that period, unexercised warrants will
be void. Warrants may be exercised in the manner described in the applicable prospectus supplement.
A
holder of a warrant will not have any of the rights of a holder of our common or preferred stock before the stock is purchased upon exercise
of the warrant. Therefore, before a warrant is exercised, the holder of the warrant will not be entitled to receive any dividend payments
or exercise any voting or other rights associated with shares of our common or preferred stock which may be purchased when the warrant
is exercised.
Transfer
Agent and Registrar
The
transfer agent and registrar, if any, for any warrants will be set forth in the applicable prospectus supplement.
DESCRIPTION
OF DEBT SECURITIES
We
summarize below some of the provisions that will apply to the debt securities unless the applicable prospectus supplement provides otherwise.
This summary may not contain all information that is important to you. The debt securities may be issued pursuant to, in the case of
senior debt securities, a senior indenture, and in the case of subordinated debt securities, a subordinated indenture, in each case in
the forms filed as exhibits to this registration statement, which we refer to as the “indentures.” The indentures
will be entered into between us and a trustee to be named prior to the issuance of any debt securities, which we refer to as the “trustee.”
The indentures will not limit the amount of debt securities that can be issued thereunder and will provide that the debt securities may
be issued from time to time in one or more series pursuant to the terms of one or more securities resolutions or supplemental indentures
creating such series.
The
complete terms of the debt securities will be contained in the applicable indenture for the particular offering of debt securities itself
which will describe the terms and definitions of the offered debt securities and contain additional information about such debt securities.
You should also read the prospectus supplement, which will contain additional information and which may update or change some of the
information below.
General
When
we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a prospectus supplement.
The prospectus supplement will set forth the following terms, as applicable, of the debt securities offered thereby:
|
● |
the
designation, aggregate principal amount, currency or composite currency and denominations; |
|
● |
the
price at which such debt securities will be issued and, if an index formula or other method is used, the method for determining amounts
of principal or interest; |
|
● |
the
maturity date and other dates, if any, on which principal will be payable; |
|
● |
whether
or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
|
● |
whether
the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of
any subordination; |
|
● |
the
interest rate (which may be fixed or variable), if any; |
|
● |
the
date or dates from which interest will accrue and on which interest will be payable, and the record dates for the payment of interest; |
|
● |
the
manner of paying principal and interest; |
|
● |
the
place or places where principal and interest will be payable; |
|
● |
the
terms of any mandatory or optional redemption by us or any third party including any sinking fund; |
|
● |
the
terms of any conversion or exchange; |
|
● |
the
terms of any redemption at the option of holders or put by the holders; |
|
● |
any
tax indemnity provisions; |
|
● |
if
the debt securities provide that payments of principal or interest may be made in a currency other than that in which debt securities
are denominated, the manner for determining such payments; |
|
● |
the
portion of principal payable upon acceleration of a Discounted Debt Security (as defined below); |
|
● |
whether
and upon what terms debt securities may be defeased; |
|
● |
any
events of default or covenants in addition to or in lieu of those set forth in the indentures; |
|
● |
provisions
for electronic issuance of debt securities or for debt securities in uncertificated form; and |
|
● |
any
additional provisions or other special terms not inconsistent with the provisions of the indentures, including any terms that may
be required or advisable under United States or other applicable laws or regulations, or advisable in connection with the marketing
of the debt securities. |
Debt
securities of any series may be issued as registered debt securities or uncertificated debt securities, in such denominations as specified
in the terms of the series.
Securities
may be issued under the indentures as Discounted Debt Securities to be offered and sold at a substantial discount from the principal
amount thereof. Special United States federal income tax and other considerations applicable thereto will be described in the prospectus
supplement relating to such Discounted Debt Securities. “Discounted Debt Security” means a security where the amount
of principal due upon acceleration is less than the stated principal amount.
We
are not obligated to issue all debt securities of one series at the same time and, unless otherwise provided in the prospectus supplement,
we may reopen a series, without the consent of the holders of the debt securities of that series, for the issuance of additional debt
securities of that series. Additional debt securities of a particular series will have the same terms and conditions as outstanding debt
securities of such series, except for the date of original issuance and the offering price, and will be consolidated with, and form a
single series with, such outstanding debt securities.
Ranking
The
senior debt securities will rank equally with all of our other senior and unsubordinated debt. Our secured debt, if any, will be effectively
senior to the senior debt securities to the extent of the value of the assets securing such debt. The subordinated debt securities will
be subordinate and junior in right of payment to all of our present and future senior indebtedness to the extent and in the manner described
in the prospectus supplement and as set forth in the board resolution, officer’s certificate or supplemental indenture relating
to such offering.
We
have only a stockholder’s claim on the assets of our subsidiaries. This stockholder’s claim is junior to the claims that
creditors of our subsidiaries have against our subsidiaries. Holders of our debt securities will be our creditors and not creditors of
any of our subsidiaries. As a result, all the existing and future liabilities of our subsidiaries, including any claims of their creditors,
will effectively be senior to the debt securities with respect to the assets of our subsidiaries. In addition, to the extent that we
issue any secured debt, the debt securities will be effectively subordinated to such secured debt to the extent of the value of the assets
securing such secured debt.
The
debt securities will be obligations exclusively of Matinas BioPharma Holdings, Inc. To the extent that our ability to service our debt,
including the debt securities, may be dependent upon the earnings of our subsidiaries, our ability to do so will be dependent on the
ability of our subsidiaries to distribute those earnings to us as dividends, loans or other payments.
Certain
Covenants
Any
covenants that may apply to a particular series of debt securities will be described in the prospectus supplement relating thereto.
Successor
Obligor
The
indentures provide that, unless otherwise specified in the securities resolution or supplemental indenture establishing a series of debt
securities, we shall not consolidate with or merge into, or transfer all or substantially all of our assets to, any person in any transaction
in which we are not the survivor, unless:
|
● |
the
person is organized under the laws of the United States or a jurisdiction within the United States; |
|
● |
the
person assumes by supplemental indenture all of our obligations under the relevant indenture, the debt securities and any coupons; |
|
● |
immediately
after the transaction no Default (as defined below) exists; and |
|
● |
we
deliver to the trustee an officers’ certificate and opinion of counsel stating that the transaction complies with the foregoing
requirements. |
In
such event, the successor will be substituted for us, and thereafter all of our obligations under the relevant indenture, the debt securities
and any coupons will terminate.
Exchange
of Debt Securities
Registered
debt securities may be exchanged for an equal aggregate principal amount of registered debt securities of the same series and date of
maturity in such authorized denominations as may be requested upon surrender of the registered debt securities at an agency of the Company
maintained for such purpose and upon fulfillment of all other requirements of such agent.
Defaults
and Remedies
Unless
the securities resolution or supplemental indenture establishing the series otherwise provides (in which event the prospectus supplement
will so state), an “Event of Default” with respect to a series of debt securities will occur if:
|
(1) |
we
default in any payment of interest on any debt securities of such series when the same becomes due and payable and the default continues
for a period of 30 days; |
|
(2) |
we
default in the payment of the principal and premium, if any, of any debt securities of such series when the same becomes due and
payable at maturity or upon redemption, acceleration or otherwise and such default shall continue for five or more days; |
|
(3) |
we
default in the performance of any of our other agreements applicable to the series and the default continues for 30 days after the
notice specified below; |
|
(4) |
a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law (as defined below) that: |
|
(A) |
is
for relief against us in an involuntary case, |
|
(B) |
appoints
a Custodian (as defined below) for us or for all or substantially all of our property, or |
|
(C) |
orders
the liquidation of us, and the order or decree remains unstayed and in effect for 90 days; |
|
(5) |
we
pursuant to or within the meaning of any Bankruptcy Law: |
|
(A) |
commence
a voluntary case, |
|
(B) |
consent
to the entry of an order for relief against us in an involuntary case, |
|
(C) |
consent
to the appointment of a Custodian for us or for all or substantially all of our property, or |
|
(D) |
make
a general assignment for the benefit of our creditors; or |
|
(6) |
there
occurs any other Event of Default provided for in such series. |
The
term “Bankruptcy Law” means Title 11 of the United States Code or any similar Federal or State law for the relief
of debtors. The term “Custodian” means any receiver, trustee, assignee, liquidator or a similar official under any
Bankruptcy Law.
“Default”
means any event which is, or after notice or passage of time would be, an Event of Default. A Default under subparagraph (3) above is
not an Event of Default until the trustee or the holders of at least 25% in principal amount of the series notify us of the Default and
we do not cure the Default within the time specified after receipt of the notice.
The
trustee may require indemnity satisfactory to it before it enforces the indentures or the debt securities of the series. Subject to certain
limitations, holders of a majority in principal amount of the debt securities of the series may direct the trustee in its exercise of
any trust or power with respect to such series. Except in the case of Default in payment on a series, the trustee may withhold from securityholders
of such series notice of any continuing Default if the trustee determines that withholding notice is in the interest of such securityholders.
We are required to furnish the trustee annually a brief certificate as to our compliance with all conditions and covenants under the
indentures.
The
indentures do not have cross-default provisions. Thus, a default by us on any other debt, including any other series of debt securities,
would not constitute an Event of Default.
Amendments
and Waivers
The
indentures and the debt securities or any coupons of the series may be amended, and any Default may be waived as follows:
Unless
the securities resolution or supplemental indenture otherwise provides (in which event the applicable prospectus supplement will so state),
the debt securities and the indentures may be amended with the consent of the holders of a majority in principal amount of the debt securities
of all series affected voting as one class. Unless the securities resolution or supplemental indenture otherwise provides (in which event
the applicable prospectus supplement will so state), a Default other than a Default in payment on a particular series may be waived with
the consent of the holders of a majority in principal amount of the debt securities of the series. However, without the consent of each
securityholder affected, no amendment or waiver may:
|
● |
change
the fixed maturity of or the time for payment of interest on any debt security; |
|
● |
reduce
the principal, premium or interest payable with respect to any debt security; |
|
● |
change
the place of payment of a debt security or the currency in which the principal or interest on a debt security is payable; |
|
● |
change
the provisions for calculating any redemption or repurchase price with respect to any debt security; |
|
● |
reduce
the amount of debt securities whose holders must consent to an amendment or waiver; |
|
● |
make
any change that materially adversely affects the right to convert any debt security; |
|
● |
waive
any Default in payment of principal of or interest on a debt security; or |
|
● |
adversely
affect any holder’s rights with respect to redemption or repurchase of a debt security. |
Without
the consent of any securityholder, the indentures or the debt securities may be amended to:
|
● |
provide
for assumption of our obligations to securityholders in the event of a merger or consolidation requiring such assumption; |
|
● |
to
cure any ambiguity, omission, defect or inconsistency; |
|
● |
to
conform the terms of the debt securities to the description thereof in the prospectus and prospectus supplement offering such debt
securities; |
|
● |
to
create a series and establish its terms; |
|
● |
to
provide for assumption of our obligations to securityholders in the event of a merger or consolidation requiring such assumption; |
|
● |
to
make any change that does not adversely affect the rights of any securityholder; |
|
● |
to
add to our covenants; or |
|
● |
to
make any other change to the indentures so long as no debt securities are outstanding. |
Conversion
Rights
Any
securities resolution or supplemental indenture establishing a series of debt securities may provide that the debt securities of such
series will be convertible at the option of the holders thereof into or for our common stock or other equity or debt instruments. The
securities resolution or supplemental indenture may establish, among other things, (1) the number or amount of shares of common stock
or other equity or debt instruments for which $1,000 aggregate principal amount of the debt securities of the series is convertible,
as may be adjusted pursuant to the terms of the relevant indenture and the securities resolution; and (2) provisions for adjustments
to the conversion rate and limitations upon exercise of the conversion right. The indentures provide that we will not be required to
make an adjustment in the conversion rate unless the adjustment would require a cumulative change of at least 1% in the conversion rate.
However, we will carry forward any adjustments that are less than 1% of the conversion rate and take them into account in any subsequent
adjustment of the conversion rate.
Legal
Defeasance and Covenant Defeasance
Debt
securities of a series may be defeased in accordance with their terms and, unless the securities resolution or supplemental indenture
establishing the terms of the series otherwise provides, as set forth below. We at any time may terminate as to a series all of our obligations
(except for certain obligations, including obligations with respect to the defeasance trust and obligations to register the transfer
or exchange of a debt security, to replace destroyed, lost or stolen debt securities and coupons and to maintain paying agencies in respect
of the debt securities) with respect to the debt securities of the series and any related coupons and the relevant indenture, which we
refer to as legal defeasance. We at any time may terminate as to a series our obligations with respect to any restrictive covenants which
may be applicable to a particular series, which we refer to as covenant defeasance.
We
may exercise our legal defeasance option notwithstanding our prior exercise of our covenant defeasance option. If we exercise our legal
defeasance option, a series may not be accelerated because of an Event of Default. If we exercise our covenant defeasance option, a series
may not be accelerated by reference to any covenant which may be applicable to a series.
To
exercise either defeasance option as to a series, we must (1) irrevocably deposit in trust with the trustee (or another trustee) money
or U.S. Government Obligations (as defined below), deliver a certificate from a nationally recognized firm of independent accountants
expressing their opinion that the payments of principal and interest when due on the deposited U.S. Government Obligations, without reinvestment,
plus any deposited money without investment will provide cash at such times and in such amounts as will be sufficient to pay the principal
and interest when due on all debt securities of such series to maturity or redemption, as the case may be; and (2) comply with certain
other conditions. In particular, we must obtain an opinion of tax counsel that the defeasance will not result in recognition of any gain
or loss to holders for federal income tax purposes.
“U.S.
Government Obligations” means direct obligations of the United States or any agency or instrumentality of the United States,
the payment of which is unconditionally guaranteed by the United States, which, in either case, have the full faith and credit of the
United States pledged for payment and which are not callable at the issuer’s option, or certificates representing an ownership
interest in such obligations.
Regarding
the Trustee
Unless
otherwise indicated in a prospectus supplement, the trustee will also act as depository of funds, transfer agent, paying agent and conversion
agent, as applicable, with respect to the debt securities. In certain circumstances, we or the securityholders may remove the trustee
as the trustee under a given indenture. The indenture trustee may also provide additional unrelated services to us as a depository of
funds, registrar, trustee and similar services.
Governing
Law
The
indentures and the debt securities will be governed by New York law, except to the extent that the Trust Indenture Act of 1939 is applicable.
DESCRIPTION
OF SUBSCRIPTION RIGHTS
We
may issue subscription rights to purchase our common stock, preferred stock or debt securities. These subscription rights may be offered
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the
subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement
with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase
any securities remaining unsubscribed for after such offering.
The
prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms relating
to the offering, including some or all of the following:
|
● |
the
price, if any, for the subscription rights; |
|
● |
the
exercise price payable for our common stock, preferred stock or debt securities upon the exercise of the subscription rights; |
|
● |
the
number of subscription rights to be issued to each stockholder; |
|
● |
the
number and terms of our common stock, preferred stock or debt securities which may be purchased per each subscription right; |
|
● |
the
extent to which the subscription rights are transferable; |
|
● |
any
other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of
the subscription rights; |
|
● |
the
date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire; |
|
● |
the
extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities or an
over-allotment privilege to the extent the securities are fully subscribed; and |
|
● |
if
applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by Matinas in connection
with the offering of subscription rights. |
DESCRIPTION
OF UNITS
We
may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued
so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights
and obligations of a holder of each included security (but, to the extent convertible securities are included in the units, the holder
of the units will be deemed the holder of the convertible securities and not the holder of the underlying securities). The unit agreement
under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time
or at any time before a specified date. The applicable prospectus supplement may describe:
|
● |
the
designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
securities may be held or transferred separately; |
|
● |
any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; |
|
● |
the
terms of the unit agreement governing the units; |
|
● |
United
States federal income tax considerations relevant to the units; and |
|
● |
whether
the units will be issued in fully registered global form. |
This
summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport
to be complete and are qualified in their entirety by reference to all provisions of the applicable unit agreement and, if applicable,
collateral arrangements and depositary arrangements relating to such units. The forms of the unit agreements and other documents relating
to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions
that may be important to you.
FORMS
OF SECURITIES
Each
debt security and, to the extent applicable, warrant, subscription right and unit, will be represented either by a certificate issued
in definitive form to a particular investor or by one or more global securities representing the entire issuance of securities. Certificated
securities in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee
as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other
interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent,
as applicable. Global securities name a depositary or its nominee as the owner of the debt securities or warrants represented by these
global securities. The depositary maintains a computerized system that will reflect each investor’s beneficial ownership of the
securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain
more fully below.
Global
Securities
Registered
Global Securities. We may issue the registered debt securities and, to the extent applicable, warrants, subscription rights and units
in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the
applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global
securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount
of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive
registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered
global security, the nominees of the depositary or any successors of the depositary or those nominees.
If
not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered
global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions
will apply to all depositary arrangements.
Ownership
of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the
depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary
will credit, on its book-entry registration and transfer system, the participants’ accounts with the respective principal or face
amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution
of the securities will designate the accounts to be credited. Ownership of beneficial interests in a registered global security will
be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect
to interests of participants, and on the records of participants, with respect to interests of persons holding through participants.
The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form.
These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities.
So
long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the
case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes
under the applicable indenture or warrant agreement. Except as described below, owners of beneficial interests in a registered global
security will not be entitled to have the securities represented by the registered global security registered in their names, will not
receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders
of the securities under the applicable indenture or warrant agreement. Accordingly, each person owning a beneficial interest in a registered
global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant,
on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable
indenture or warrant agreement. We understand that under existing industry practices, if we request any action of holders or if an owner
of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take
under the applicable indenture or warrant agreement, the depositary for the registered global security would authorize the participants
holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning
through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them.
Principal,
premium, if any, and interest payments on debt securities and any payments to holders with respect to warrants represented by a registered
global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may
be, as the registered owner of the registered global security. None of Matinas, the trustees, the warrant agents or any other agent of
Matinas, agent of the trustees or agent of the warrant agents will have any responsibility or liability for any aspect of the records
relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising
or reviewing any records relating to those beneficial ownership interests.
We
expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal,
premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will
immediately credit participants’ accounts in amounts proportionate to their respective beneficial interests in that registered
global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests
in a registered global security held through participants will be governed by standing customer instructions and customary practices,
as is now the case with the securities held for the accounts of customers in bearer form or registered in “street name,”
and will be the responsibility of those participants.
If
the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue
as depositary or ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days,
we will issue securities in definitive form in exchange for the registered global security that had been held by the depositary. Any
securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary
gives to the relevant trustee or warrant agent or other relevant agent of ours or theirs. It is expected that the depositary’s
instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests
in the registered global security that had been held by the depositary.
PLAN
OF DISTRIBUTION
We
may sell the securities being offered pursuant to this prospectus through underwriters or dealers, through agents, or directly to one
or more purchasers or through a combination of these methods. The applicable prospectus supplement will describe the terms of the offering
of the securities, including:
|
● |
the
name or names of any underwriters, if any, and if required, any dealers or agents; |
|
|
|
|
● |
the
purchase price of the securities and the proceeds we will receive from the sale; |
|
|
|
|
● |
any
underwriting discounts and other items constituting underwriters’ compensation; |
|
|
|
|
● |
any
discounts or concessions allowed or reallowed or paid to dealers; and |
|
|
|
|
● |
any
securities exchange or market on which the securities may be listed. |
We
may distribute the securities from time to time in one or more transactions at:
|
● |
a
fixed price or prices, which may be changed; |
|
|
|
|
● |
market
prices prevailing at the time of sale; |
|
|
|
|
● |
prices
related to such prevailing market prices; or |
|
|
|
|
● |
negotiated
prices. |
Only
underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.
If
underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each
underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters
and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented
by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is
used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale,
the offered securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale.
Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will
be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.
We
may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price,
with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment
option will be set forth in the prospectus supplement for those securities.
If
we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the
securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by
the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.
We
may sell the securities directly or through agents we designate from time to time. We will name any agent involved in the offering and
sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement
states otherwise, any agent will act on a best-efforts basis for the period of its appointment.
We
may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering
price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified
date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts
in the prospectus supplement.
In
connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the
securities for whom they act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to
or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution
of the securities, and any institutional investors or others that purchase securities directly and then resell the securities, may be
deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the securities by
them may be deemed to be underwriting discounts and commissions under the Securities Act.
We
may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities
Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters
may engage in transactions with, or perform services for, us in the ordinary course of business.
In
addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities not covered
by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection
with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities
covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others
to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities
covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event
of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement.
The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in
a post-effective amendment.
To
facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain,
or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which involves
the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances, such
persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option
granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing
securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating
in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect
of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise
prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction
as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.
All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time
without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is currently no market for any of
the offered securities, other than our common stock which is listed on the NYSE American. We have no current plans for listing of the
preferred stock, warrants, units or subscription rights on any securities exchange or quotation system; any such listing with respect
to any particular preferred stock, warrants, units or subscription rights will be described in the applicable prospectus supplement or
other offering materials, as the case may be. Any underwriters to whom securities are sold by us for public offering and sale may make
a market in the securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without
notice.
In
order to comply with the securities laws of some states, if applicable, the securities offered pursuant to this prospectus will be sold
in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless
they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and complied with.
Under Rule 15c6-1 of the Exchange
Act, unless the parties to any such trade expressly agree otherwise. trades in the secondary market generally are required to settle
(a) in two business days, prior to May 28, 2024 and (b) in one business day starting on May 28, 2024. The applicable prospectus supplement
may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your
securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day (prior to May 28,
2024) or second business day (on or after May 28, 2024) before the original issue date for your securities, you will be required, by
virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date
for your securities, to make alternative settlement arrangements to prevent a failed settlement.
This prospectus, any applicable
prospectus supplement and any applicable pricing supplement in electronic format may be made available on the Internet sites of, or through
other online services maintained by, us and/or one or more of the agents and/or dealers participating in an offering of securities, or
by their affiliates. In those cases, prospective investors may be able to view offering terms online and, depending upon the particular
agent or dealer, prospective investors may be allowed to place orders online.
Other than this prospectus,
any applicable prospectus supplement and any applicable pricing supplement in electronic format, the information on our website or the
website of any agent or dealer, and any information contained in any other website maintained by any agent or dealer:
|
● |
is not part of this prospectus, any applicable prospectus
supplement or any applicable pricing supplement or the registration statement of which they form a part; |
|
● |
has not been approved or endorsed by us or by any agent or dealer
in its capacity as an agent or dealer, except, in each case, with respect to the respective website maintained by such entity; and |
|
● |
should not be relied upon by investors. |
There can be no assurance
that we will sell all or any of the securities offered by this prospectus.
This prospectus may also be
used in connection with any issuance of common stock or preferred stock upon exercise of a warrant if such issuance is not exempt from
the registration requirements of the Securities Act.
In addition, we may issue
the securities as a dividend or distribution or in a subscription rights offering to our existing securityholders. In some cases, we
or dealers acting with us or on our behalf may also purchase securities and reoffer them to the public by one or more of the methods
described above. This prospectus may be used in connection with any offering of our securities through any of these methods or other
methods described in the applicable prospectus supplement.
Under Rule 15c6-1 of the
Exchange Act, unless the parties to any such trade expressly agree otherwise. trades in the secondary market generally are required
to settle (a) in two business days, prior to May 28, 2024 and (b) in one business day starting on May 28, 2024. The applicable
prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days
after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the
third business day (prior to May 28, 2024) or second business day (on or after May 28, 2024) before the original issue date for your
securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three
scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed
settlement.
This prospectus, any applicable
prospectus supplement and any applicable pricing supplement in electronic format may be made available on the Internet sites of, or through
other online services maintained by, us and/or one or more of the agents and/or dealers participating in an offering of securities, or
by their affiliates. In those cases, prospective investors may be able to view offering terms online and, depending upon the particular
agent or dealer, prospective investors may be allowed to place orders online.
Other than this prospectus, any applicable prospectus
supplement and any applicable pricing supplement in electronic format, the information on our website or the website of any agent or
dealer, and any information contained in any other website maintained by any agent or dealer:
| ● | is not part of this prospectus, any
applicable prospectus supplement or any applicable pricing supplement or the registration
statement of which they form a part; |
| ● | has not been approved or
endorsed by us or by any agent or dealer in its capacity as an agent or dealer, except, in
each case, with respect to the respective website maintained by such entity; and |
| ● | should not be relied upon
by investors. |
There can be no assurance that we will sell all or any
of the securities offered by this prospectus.
This prospectus may also be used in connection with
any issuance of common stock or preferred stock upon exercise of a warrant if such issuance is not exempt from the registration requirements
of the Securities Act.
In addition, we may issue the securities as a dividend
or distribution or in a subscription rights offering to our existing securityholders. In some cases, we or dealers acting with us or
on our behalf may also purchase securities and reoffer them to the public by one or more of the methods described above. This prospectus
may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable
prospectus supplement.
LEGAL
MATTERS
Unless
otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us
by Lowenstein Sandler LLP, New York, New York. If the validity of the securities offered hereby in connection with offerings made pursuant
to this prospectus are passed upon by counsel for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus
supplement relating to such offering.
EXPERTS
The consolidated
balance sheets of Matinas BioPharma Holdings, Inc. and Subsidiaries (the “Company”) as of December 31, 2022 and 2021, and
the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the
years then ended, have been audited by EisnerAmper LLP, an independent registered public accounting firm, as stated in their
report which is incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance
on the report of such firm given upon their authority as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC’s
rules, this prospectus and any prospectus supplement, which form a part of the registration statement, do not contain all the information
that is included in the registration statement. You will find additional information about us in the registration statement. Any statements
made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the
documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding
of the document or matter.
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read, without charge, and copy
the documents we file at the SEC’s public reference rooms in Washington, D.C. at 100 F Street, NE, Room 1580, Washington, DC 20549.
You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330
for further information on the public reference rooms. Our SEC filings are also available to the public at no cost from the SEC’s
website at http://www.sec.gov.
INCORPORATION
OF DOCUMENTS BY REFERENCE
We
have filed a registration statement on Form S-3 with the Securities and Exchange Commission under the Securities Act. This prospectus
is part of the registration statement but the registration statement includes and incorporates by reference additional information and
exhibits. The Securities and Exchange Commission permits us to “incorporate by reference” the information contained in documents
we file with the Securities and Exchange Commission, which means that we can disclose important information to you by referring you to
those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part
of this prospectus and you should read it with the same care that you read this prospectus. Information that we file later with the Securities
and Exchange Commission will automatically update and supersede the information that is either contained, or incorporated by reference,
in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed with
the Securities and Exchange Commission, and incorporate by reference in this prospectus:
|
● |
Annual
Report on Form 10-K for the year ended December 31, 2022, filed on March 15, 2023; |
|
|
|
|
● |
Quarterly
Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 10, 2023; |
|
|
|
|
● |
Definitive
Proxy Statement on Schedule 14A, filed on September 22, 2022; |
|
|
|
|
● |
Current
Reports on Form 8-K, filed on January 12, 2023, January 30, 2023, March 15, 2023, April 18, 2023 and May 10, 2023 (other than any
portions thereof deemed furnished and not filed); and |
|
|
|
|
● |
The
description of our common stock contained in our Form 8-A, filed on March 1, 2017. |
We
also incorporate by reference all additional documents that we file with the Securities and Exchange Commission under the terms of Sections
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, that are made after the initial filing date of the registration
statement of which this prospectus is a part until the offering of the particular securities covered by a prospectus supplement or term
sheet has been completed. We are not, however, incorporating, in each case, any documents or information that we are deemed to furnish
and not file in accordance with Securities and Exchange Commission rules.
You
may request, and we will provide you with, a copy of these filings, at no cost, by contacting us at:
Investor
Relations Department
Matinas
BioPharma Holdings, Inc.
1545
Route 206 South
Suite
302
Bedminster,
NJ 07921
Telephone
number: (908) 484-8805
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jul 2023 to Jul 2024